Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection

设为首页

收藏本站

网站地图 | English | 公务邮箱

About the library

Background
History
Leadership
Organization

Readers' Guide

Opening Hours
Collections
Help Via Email

Publications

Electronic Information Resources

Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection

详细信息查看全文

作者：Hongjie Qiu^a ; Shihui Sun^a ; He Xiao^b ; Jiannan Feng^b ; Yan Guo^a ; Wanbo Tai^a ; ^c ; Yufei Wang^a ; ^c ; Lanying Du^c ; Guangyu Zhao^a ; ^{guangyu0525@163.com" class="auth_mail" title="E-mail the corresponding author} ; Yusen Zhou^a ; ^{yszhou@bmi.ac.cn" class="auth_mail" title="E-mail the corresponding author}
关键词：MERS-CoV ; Receptor-binding domain ; Humanized monoclonal antibody ; Protection ; Treatment ; Lethal infection
刊名：Antiviral Research
出版年：2016
出版时间：August 2016
年：2016
卷：132
期：Complete
页码：141-148
全文大小：1858 K

文摘

•: A humanized monoclonal antibody (mAb) against Middle East respiratory syndrome coronavirus (MERS-CoV), hMS-1, was generated.
•: hMS-1 bound to the MERS-CoV receptor binding domain (RBD) with high affinity.
•: hMS-1 neutralized MERS-CoV infection by blocking the binding of MERS-CoV RBD to the hDPP4 receptor.
•: Humanized mAb hMS-1 recognized conserved RBD epitopes and cross-neutralized MERS-CoV evolved strains.
•: Single-dose treatment of mAb hMS-1 provided full protection from lethal MERS-CoV infection in an hDPP4-Tg mouse model.